Results 11 to 20 of about 12,875 (237)
Switching to Biosimilars in Inflammatory Rheumatic Conditions: Current Knowledge [PDF]
European Medical Journal Rheumatology, 2018 Biosimilars are more affordable versions of previously approved biopharmaceuticals that are designed to reduce healthcare expenditure and increase patient access to this therapeutic class. To achieve their economic potential, many European countries have
Filipe C. Araújo +2 more
doaj +1 more source
Journal of Oncology Practice, 2017 Biosimilar therapeutic proteins in oncology offer the potential to decrease costs while providing safety and efficacy profiles consistent with their respective reference or originator products. Biosimilars have a number of important differences from generic small-molecule drugs, including manufacturing processes that are unique from their reference ...
R. Donald Harvey
openaire +3 more sources
Monoclonal antibody biosimilars for cancer treatment [PDF]
iScienceSummary: Monoclonal antibodies are important cancer medicines. The European Medicines Agency (EMA) approved 48 and the Food and Drug Administration (FDA) 56 anticancer monoclonal antibody-based therapies.
Linda N. Broer +6 more
doaj +2 more sources
Journal of the European Academy of Dermatology and Venereology, 2018 Linked article: This is a commentary on P. Yamauchi et al., pp. 1066–1074 in this issue.
Sandeep, Parsad, Chadi, Nabhan
+10 more sources
Biosimilars for Haematologic Malignancies: The Path to Sustainable Care
European Medical Journal Hematology, 2017 The main objectives of this symposium were to review the value of biosimilars in sustainable treatment for haematologic malignancies and to recognise the developmental differences between biosimilars and their reference products.
Paul Cornes +2 more
doaj +1 more source
Analysis of Suffix Use for Biosimilar Product Identification in Postmarketing Adverse Event Reporting. [PDF]
Clin Pharmacol TherAccurate identification of medicines used in adverse event reports is crucial for effective postmarketing safety surveillance. The US Food and Drug Administration's (FDA) four‐letter suffix naming convention was designed to facilitate accurate biological product identification, but the extent to which these suffixes have been incorporated into ...
Stojanovic D +3 more
europepmc +2 more sources
, 2022 Introduced in the 1980s, biologic medications have since become important tools in modern medicine. However, biologics are expensive, greatly affecting the healthcare budgets of both underdeveloped and developed countries. Fortunately, biosimilars, which
core +1 more source
Therapeutische Umschau, 2011 Die Bewertung von Biosimilars stellt eine Herausforderung für alle an der Zulassung und an der Arzneimittelauswahl Beteiligten im Gesundheitswesen dar. Bewertungskriterien sind wie bei allen Arzneimitteln Qualität, Wirksamkeit, Sicherheit/Verträglichkeit und Wirtschaftlichkeit.
openaire +6 more sources
Ever-changing landscape of biosimilars in Canada; findings and implications from a global perspective [PDF]
, 2019 Siu et al. have comprehensively assessed the rapidly changing regulation and reimbursement environment for biologicals and biosimilars in Canada and the resultant ...
Allocati, Eleonora +2 more
core +5 more sources
Budget Impact Analysis of Biosimilar Products in Spain in the Period 2009–2019
Pharmaceuticals, 2021 Since the first biosimilar medicine, Omnitrope® (active substance somatropin) was approved in 2006, 53 biosimilars have been authorized in Spain. We estimate the budget impact of biosimilars in Spain from the perspective of the National Health System ...
Manuel García-Goñi +3 more
doaj +1 more source